• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Building a Biotech Basket

Borrowing a page from a master investor's playbook.
By SHAM GAD Jun 11, 2014 | 05:00 PM EDT
Stocks quotes in this article: KERX, AVEO, KIN, IDIX

Tuesday, I wrote about value investor Seth Klarman's multi-year foray into the land of biotech stocks and why such a highly regarded value investor would venture into stocks that are widely considered speculative. Most biotechs generate no profits, employ a lot of leverage or issue equity to fund drugs that often never realize any commercial value. But for those biotechs that do succeed, the payoff is many fold. Look at Klarman's recent experience with Idenix Pharmaceuticals (IDIX). Shortly after Klarman's Baupost Group took a 30% stake in the company, Merck (MRK) made an offer to buy it at a 230% premium.

Over the past several years, Klarman has taken many small stakes in various biotechs. Why not copy the master and create your own basket of biotechs? Instead of betting a lot on one, bet a little on several. A single winner will more than make up for a few duds. And if you select carefully, odds are even better that the basket will produce more than one winner and very few losers.

Let's start with the obvious picks, the ones that Klarman still owns today that have not spiked up on a buyout or other milestones. Keryx Biopharmaceuticals (KERX) is a new position initiated by Baupost during the most-recent quarter. Shares trade for about $14, up from a 52-week low of $6, valuing the company at $1.3 billion. Keryx focuses on drugs that treat renal disease.

AVEO Pharmaceuticals (AVEO) is micro-cap biotech focusing on cancer drugs. The company has a market cap of $65 million and Baupost has an approximately 8% stake. AVEO currently has two compounds in Phase 1 and Phase 2 studies.

Kindred Biosciences (KIN) is a name I have written about several times and probably the most intriguing idea. It focuses on drugs for pets -- namely cats and dogs. Shares have been quite volatile. When I first mentioned the company, shares were trading in the mid-teens and went as high as $23 before coming back to $15. Currently, shares trade around $19, valuing the company at approximately $370 million.

Our little biotech basket will consist of these three names for now. While there are dozens of biotech companies, I want to limit the basket to names that have been either screened by other investors or have candidates that are in latter stages of the trial cycle. Those that make the cut will be added, and I hope to have five to seven names in the basket. Each month I will track the performance of this basket and see how it stands up against other biotech exchange-traded funds.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gad was long KIN, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Dividend Hunters Will Like the Combination Found in Global Medical REIT Shares

Chris Versace
Mar 7, 2021 9:00 AM EST

More people seeking more healthcare and medical attention will create a rising tide for GMRE's addressable market.

Walgreens Boots Alliance Is Likely to Weaken Further

Bruce Kamich
Mar 5, 2021 12:44 PM EST

Let's check out the charts and indicators.

Emergent BioSolutions Turns Bearish, So Beware

Bruce Kamich
Mar 4, 2021 8:27 AM EST

A break in a key support level could precipitate further declines in the life sciences company's shares.

Centene Charts Remain Weak and Vulnerable

Bruce Kamich
Mar 3, 2021 1:35 PM EST

Let's review the charts and indicators.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Bruce Kamich
Mar 3, 2021 12:20 PM EST

Stand aside for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login